Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Michael S. Rogers, Ph.D.


The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. R01CA211646 (ZETTER, BRUCE R) Dec 23, 2016 - Nov 30, 2020
    Assays to Identify Prostate Cancer Therapeutics Targeting Antizyme Inhibitor
    Role: Principal Investigator
  2. R01EY018829 (ROGERS, MICHAEL SEAN) May 1, 2008 - Apr 30, 2014
    Novel Angiogenesis Inhibitors Targeting the Anthrax Toxin Receptors
    Role: Principal Investigator
  3. R21NS059411 (ROGERS, MICHAEL SEAN) Mar 5, 2007 - Feb 28, 2009
    Assay for Inhibitors of Angiogenesis and Anthrax Toxin Receptor 1
    Role: Principal Investigator

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Fattori V, Franklin NS, Gonzalez-Cano R, Peterse D, Ghalali A, Madrian E, Verri WA, Andrews N, Woolf CJ, Rogers MS. Nonsurgical mouse model of endometriosis-associated pain that responds to clinically active drugs. Pain. 2020 06; 161(6):1321-1331. PMID: 32132396.
    Citations: 4     Fields:    Translation:HumansAnimals
  2. Ghalali A, Rice JM, Kusztos A, Jernigan FE, Zetter BR, Rogers MS. Developing a novel FRET assay, targeting the binding between Antizyme-AZIN. Sci Rep. 2019 03 15; 9(1):4632. PMID: 30874587.
    Citations: 2     Fields:    Translation:HumansAnimalsCells
  3. Dao DT, Anez-Bustillos L, Jabbouri SS, Pan A, Kishikawa H, Mitchell PD, Fell GL, Baker MA, Watnick RS, Chen H, Rogers MS, Bielenberg DR, Puder M. A paradoxical method to enhance compensatory lung growth: Utilizing a VEGF inhibitor. PLoS One. 2018; 13(12):e0208579. PMID: 30566445.
    Citations: 1     Fields:    Translation:AnimalsCells
  4. Dao DT, Anez-Bustillos L, Ourieff J, Pan A, Mitchell PD, Kishikawa H, Fell GL, Baker MA, Watnick RS, Chen H, Hamilton TE, Rogers MS, Bielenberg DR, Puder M. Heparin impairs angiogenic signaling and compensatory lung growth after left pneumonectomy. Angiogenesis. 2018 11; 21(4):837-848. PMID: 29956017.
    Citations: 1     Fields:    Translation:HumansAnimals
  5. Khajavi M, Zhou Y, Birsner AE, Bazinet L, Rosa Di Sant A, Schiffer AJ, Rogers MS, Krishnaji ST, Hu B, Nguyen V, Zon L, D'Amato RJ. Identification of Padi2 as a novel angiogenesis-regulating gene by genome association studies in mice. PLoS Genet. 2017 Jun; 13(6):e1006848. PMID: 28617813.
    Citations: 3     Fields:    Translation:HumansAnimalsCells
  6. Rogers MS, Novak K, Zurakowski D, Cryan LM, Blois A, Lifshits E, Bø TH, Oyan AM, Bender ER, Lampa M, Kang SY, Naxerova K, Kalland KH, Straume O, Akslen LA, Watnick RS, Folkman J, Naumov GN. Spontaneous reversion of the angiogenic phenotype to a nonangiogenic and dormant state in human tumors. Mol Cancer Res. 2014 May; 12(5):754-64. PMID: 24574516.
    Citations: 4     Fields:    Translation:HumansAnimalsCells
  7. Adini I, Ghosh K, Adini A, Chi ZL, Yoshimura T, Benny O, Connor KM, Rogers MS, Bazinet L, Birsner AE, Bielenberg DR, D'Amato RJ. Melanocyte-secreted fibromodulin promotes an angiogenic microenvironment. J Clin Invest. 2014 Jan; 124(1):425-36. PMID: 24355922.
    Citations: 24     Fields:    Translation:HumansAnimalsCells
  8. D'Amato RJ, Lentzsch S, Rogers MS. Pomalidomide is strongly antiangiogenic and teratogenic in relevant animal models. Proc Natl Acad Sci U S A. 2013 Dec 10; 110(50):E4818. PMID: 24302770.
    Citations: 3     Fields:    Translation:AnimalsCells
  9. Cryan LM, Habeshian KA, Caldwell TP, Morris MT, Ackroyd PC, Christensen KA, Rogers MS. Identification of small molecules that inhibit the interaction of TEM8 with anthrax protective antigen using a FRET assay. J Biomol Screen. 2013 Jul; 18(6):714-25. PMID: 23479355.
    Citations: 7     Fields:    Translation:HumansCells
  10. Cryan LM, Bazinet L, Habeshian KA, Cao S, Clardy J, Christensen KA, Rogers MS. 1,2,3,4,6-Penta-O-galloyl-ß-D-glucopyranose inhibits angiogenesis via inhibition of capillary morphogenesis gene 2. J Med Chem. 2013 Mar 14; 56(5):1940-5. PMID: 23394144.
    Citations: 5     Fields:    Translation:HumansAnimalsCells
  11. Rogers MS, Adini I, McBride AF, Birsner AE, D'Amato RJ. The albino mutation of tyrosinase alters ocular angiogenic responsiveness. Angiogenesis. 2013 Jul; 16(3):639-46. PMID: 23423728.
    Citations: 4     Fields:    Translation:HumansAnimalsCells
  12. Rogers MS, D'Amato RJ. Common polymorphisms in angiogenesis. Cold Spring Harb Perspect Med. 2012 Nov 01; 2(11). PMID: 23125197.
    Citations: 7     Fields:    Translation:HumansAnimals
  13. Cao S, Cryan L, Habeshian KA, Murillo C, Tamayo-Castillo G, Rogers MS, Clardy J. Phenolic compounds as antiangiogenic CMG2 inhibitors from Costa Rican endophytic fungi. Bioorg Med Chem Lett. 2012 Sep 15; 22(18):5885-8. PMID: 22910038.
    Citations: 6     Fields:    Translation:HumansAnimalsCells
  14. Rogers MS, Cryan LM, Habeshian KA, Bazinet L, Caldwell TP, Ackroyd PC, Christensen KA. A FRET-based high throughput screening assay to identify inhibitors of anthrax protective antigen binding to capillary morphogenesis gene 2 protein. PLoS One. 2012; 7(6):e39911. PMID: 22768167.
    Citations: 9     Fields:    Translation:AnimalsCells
  15. Rogers MS, Boyartchuk V, Rohan RM, Birsner AE, Dietrich WF, D'Amato RJ. The classical pink-eyed dilution mutation affects angiogenic responsiveness. PLoS One. 2012; 7(5):e35237. PMID: 22615734.
    Citations: 6     Fields:    Translation:Animals
  16. Cryan LM, Rogers MS. Targeting the anthrax receptors, TEM-8 and CMG-2, for anti-angiogenic therapy. Front Biosci (Landmark Ed). 2011 Jan 01; 16:1574-88. PMID: 21196249.
    Citations: 23     Fields:    Translation:HumansAnimalsCells
  17. Nakai K, Rogers MS, Baba T, Funakoshi T, Birsner AE, Luyindula DS, D'Amato RJ. Genetic loci that control the size of laser-induced choroidal neovascularization. FASEB J. 2009 Jul; 23(7):2235-43. PMID: 19237505.
    Citations: 11     Fields:    Translation:AnimalsCells
  18. Rogers MS, Christensen KA, Birsner AE, Short SM, Wigelsworth DJ, Collier RJ, D'Amato RJ. Mutant anthrax toxin B moiety (protective antigen) inhibits angiogenesis and tumor growth. Cancer Res. 2007 Oct 15; 67(20):9980-5. PMID: 17942931.
    Citations: 16     Fields:    Translation:HumansAnimalsCells
  19. Rogers MS, Birsner AE, D'Amato RJ. The mouse cornea micropocket angiogenesis assay. Nat Protoc. 2007; 2(10):2545-50. PMID: 17947997.
    Citations: 58     Fields:    Translation:Animals
  20. Folkman J, Rogers MS. Thalidomide for multiple myeloma. N Engl J Med. 2006 Jun 01; 354(22):2389-90; author reply 2389-90. PMID: 16738279.
    Citations: 2     Fields:    Translation:Humans
  21. Rogers MS, D'Amato RJ. The effect of genetic diversity on angiogenesis. Exp Cell Res. 2006 Mar 10; 312(5):561-74. PMID: 16321383.
    Citations: 20     Fields:    Translation:HumansAnimals
  22. Shaked Y, Bertolini F, Man S, Rogers MS, Cervi D, Foutz T, Rawn K, Voskas D, Dumont DJ, Ben-David Y, Lawler J, Henkin J, Huber J, Hicklin DJ, D'Amato RJ, Kerbel RS. Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell. 2005 Jan; 7(1):101-11. PMID: 15652753.
    Citations: 104     Fields:    Translation:HumansAnimalsCells
  23. Rogers MS, Rohan RM, Birsner AE, D'Amato RJ. Genetic loci that control the angiogenic response to basic fibroblast growth factor. FASEB J. 2004 Jul; 18(10):1050-9. PMID: 15226265.
    Citations: 16     Fields:    Translation:Animals
  24. Rogers MS, Rohan RM, Birsner AE, D'Amato RJ. Genetic loci that control vascular endothelial growth factor-induced angiogenesis. FASEB J. 2003 Nov; 17(14):2112-4. PMID: 12958152.
    Citations: 20     Fields:    Translation:Animals
  25. Browder T, Folkman J, Hahnfeldt P, Heymach J, Hlatky L, Kieran M, Rogers MS. Antiangiogenic therapy and p53. Science. 2002 Jul 26; 297(5581):471; discussion 471. PMID: 12143876.
    Citations: 4     Fields:    Translation:HumansAnimalsCells
  26. Lentzsch S, Rogers MS, LeBlanc R, Birsner AE, Shah JH, Treston AM, Anderson KC, D'Amato RJ. S-3-Amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice. Cancer Res. 2002 Apr 15; 62(8):2300-5. PMID: 11956087.
    Citations: 18     Fields:    Translation:HumansAnimalsCells
  27. D'Amato RJ, Lentzsch S, Anderson KC, Rogers MS. Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma. Semin Oncol. 2001 Dec; 28(6):597-601. PMID: 11740816.
    Citations: 9     Fields:    Translation:Humans
  28. Rogers MS, Kobayashi T, Pittelkow MR, Strehler EE. Human calmodulin-like protein is an epithelial-specific protein regulated during keratinocyte differentiation. Exp Cell Res. 2001 Jul 15; 267(2):216-24. PMID: 11426940.
    Citations: 8     Fields:    Translation:HumansAnimalsCells
  29. Rogers MS, Strehler EE. The tumor-sensitive calmodulin-like protein is a specific light chain of human unconventional myosin X. J Biol Chem. 2001 Apr 13; 276(15):12182-9. PMID: 11278607.
    Citations: 25     Fields:    Translation:HumansCells
  30. Rogers MS, Foley MA, Crotty TB, Hartmann LC, Ingle JN, Roche PC, Strehler EE. Loss of immunoreactivity for human calmodulin-like protein is an early event in breast cancer development. Neoplasia. 1999 Aug; 1(3):220-5. PMID: 10935476.
    Citations: 8     Fields:    Translation:HumansAnimalsCells
  31. Qian H, Rogers MS, Schleucher J, Edlund U, Strehler EE, Sethson I. Sequential assignment of 1H, 15N, 13C resonances and secondary structure of human calmodulin-like protein determined by NMR spectroscopy. Protein Sci. 1998 Nov; 7(11):2421-30. PMID: 9828009.
    Citations: 2     Fields:    Translation:HumansCells
  32. Garamszegi N, Garamszegi ZP, Rogers MS, DeMarco SJ, Strehler EE. Application of a chimeric green fluorescent protein to study protein-protein interactions. Biotechniques. 1997 Nov; 23(5):864-6, 868-70, 872. PMID: 9383552.
    Citations: 2     Fields:    Translation:HumansCells
  33. Borrowman A, Rogers MS, O'Neill KL. An improved washing apparatus for nucleoside phosphorylation assays. Biotechniques. 1993 Sep; 15(3):402-4, 406. PMID: 8217151.
    Citations:    Fields:    Translation:Cells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Rogers's Networks
Click the
buttons for more information and interactive visualizations!
Concepts (193)
Co-Authors (22)
Similar People (60)
Same Department 
Physical Neighbors
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.